Middle East & Africa Pharmacovigilance Market Size & Outlook
The pharmacovigilance market in Middle East & Africa is expected to reach a projected revenue of US$ 455.5 million by 2033. A compound annual growth rate of 5% is expected of Middle East & Africa pharmacovigilance market from 2026 to 2033.
The MEA pharmacovigilance market generated a revenue of USD 302.4 million in 2025.
The market is expected to grow at a CAGR of 5% from 2026 to 2033.
In terms of segment, phase iv was the largest revenue generating product life cycle in 2025.
Phase III is the most lucrative product life cycle segment registering the fastest growth during the forecast period.
Country-wise, Saudi Arabia is expected to register the highest CAGR from 2026 to 2033.
MEA data book summary
Market revenue in 2025
USD 302.4 million
Market revenue in 2033
USD 455.5 million
Growth rate
5% (CAGR from 2026 to 2033)
Largest segment
Phase iv
Fastest growing segment
Phase III
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Pre Clinical, Phase I, Phase II, Phase III, Phase IV
Key market players worldwide
Accenture PLC Class A, IQVIA Holdings Inc, Cognizant Technology Solutions Corp Class A, Linical Americas, International Business Machines Corp, Labcorp Holdings Inc, ArisGlobal, Capgemini SE, ITClinical, Icon PLC, TAKE Solutions, PAREXEL, Wipro Ltd ADR, United Biosource Corporation, FMD K&L, BioClinica
Other key industry trends
In terms of revenue, MEA region accounted for 3.5% of the global pharmacovigilance market in 2025.
Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 4,742.2 million by 2033.
This region is anticipated to witness steady growth over the forecast period owing to the growing market for biopharmaceuticals, untapped opportunities pertinent to the entire clinical trial cycle, and a rise in supportive government initiatives. The lack of coordinated PV systems and the increasing need for efficient ADR reporting systems are positively impacting the overall market in this region.
This is a result of illicit drug consumption, lack of stringent regulatory framework, and low awareness. The establishment of PV organizations, such as the International Society of PV (ISoP), to strengthen PV activities and promote awareness regarding patient safety, is also anticipated to increase growth potential in this region.
An increase in regulatory collaborations is also a driver for the regional market. For instance, Middle East Regulatory Network (MERN) and Saudi Food and Drug Authority (SFDA) partnered to develop regulatory practices for enabling quality drug development and drug safety monitoring.
Middle East & Africa Pharmacovigilance Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmacovigilance Market Outlook will help companies and investors design strategic landscapes.
Phase Iv was the largest segment with a revenue share of 81.42% in 2025.
Horizon Databook has segmented the Middle East & Africa pharmacovigilance market based on pre clinical, phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2021 to 2033.
This region is anticipated to witness steady growth over the forecast period owing to the growing market for biopharmaceuticals, untapped opportunities pertinent to the entire clinical trial cycle, and a rise in supportive government initiatives. The lack of coordinated PV systems and the increasing need for efficient ADR reporting systems are positively impacting the overall market in this region.
This is a result of illicit drug consumption, lack of stringent regulatory framework, and low awareness. The establishment of PV organizations, such as the International Society of PV (ISoP), to strengthen PV activities and promote awareness regarding patient safety, is also anticipated to increase growth potential in this region.
An increase in regulatory collaborations is also a driver for the regional market. For instance, Middle East Regulatory Network (MERN) and Saudi Food and Drug Authority (SFDA) partnered to develop regulatory practices for enabling quality drug development and drug safety monitoring.
Middle East & Africa Pharmacovigilance Market Product Life Cycle Outlook (Revenue, USD Million , 2021-2033)
Pre Clinical
Phase I
Phase II
Phase III
Phase IV
Middle East & Africa Pharmacovigilance Market Service Provider Outlook (Revenue, USD Million , 2021-2033)
In House
Contract outsourcing
Middle East & Africa Pharmacovigilance Market Type Outlook (Revenue, USD Million , 2021-2033)
Spontaneous reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining
Middle East & Africa Pharmacovigilance Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceuticals
Biotechnology Companies
Medical Device Manufacturers
Others
Middle East & Africa Pharmacovigilance Market Therapeutic Area Outlook (Revenue, USD Million , 2021-2033)
Oncology
Neurology
Cardiology
Respiratory Systems
Others
Middle East & Africa Pharmacovigilance Market Process Flow Outlook (Revenue, USD Million , 2021-2033)
Case Data Management
Signal Detection
Risk Management System
Reasons to subscribe to Pharmacovigilance Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmacovigilance Market Outlook databook
Our clientele includes a mix of Pharmacovigilance Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa Pharmacovigilance Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa Pharmacovigilance Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Middle East Africa Pharmacovigilance Market, 2021-2033 (US$M)